This program aims to develop anti-MUC16 × CD3 therapeutic Bispecific Antibody for immuno-oncology.
Mucin-16 (MUC16, CA125) is the largest member of the mucin family, consisting of high-molecular-weight glycoproteins synthesized by human epithelial cells to protect and heal the epithelial surface. The extracellular portion of MUC16 can be extracted and released into serum as circulating epitope, cancer antigen 125 (CA125), which is a serum biomarker for mature ovarian cancer (OC). Not only does MUC16 used in clinical diagnosis but also for the prognosis of the disease. MUC16 overexpression on the cancer cell surface is associated with poor prognosis in pancreatic cancer, colon cancer, and OC patients. In particular, MUC16 produces a key tumor-promoting effect in OC, especially on the cytoplasmic tail domain (CTD) of MUC16.
Given the reasons mentioned above, we propose a novel combination- MUC16 / CD3 therapeutic BiTE, of which we believe will provide insights for the next-generation cancer treatment.
MUC16 is a high-molecular-weight type I transmembrane glycoprotein containing more than 22,000 amino acids. It is made up of an extracellular N-terminal region, in which the heavy glycosylation region is interspersed with sea urchin sperm protein, enterokinase and agrin (SEA); a transmembrane region; and a 32 amino acid short cytoplasmic tail region (CTD).
Fig.1 Mesothelin binding to CA125/MUC16 promotes pancreatic cancer.
In summary, the emergence of novel MUC16 antigen as a potential target for T cell-redirected antibody (TRAB) therapy has brought hope to the development of future immunotherapeutic strategies.
Here are some published data about MUC16 × CD3 working as a potential target for cancer immunotherapy.
Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-MUC16 × CD3 therapeutic Bispecific Antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use
Download our brochure